Galmed Pharmaceuticals Ltd. GLMD
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS2.39
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $0 | $0 | $2.0M | $1.1M | $467.0K |
| R&D | $4.9M | $3.0M | $3.6M | $13.0M | $27.2M | $26.1M | $18.2M | $8.3M | $9.7M | $14.3M |
| SG&A | $3.6M | $3.3M | $3.9M | $4.7M | $5.7M | $4.1M | $4.2M | $4.4M | $3.8M | $3.1M |
| Total operating expenses | $8.5M | $6.3M | $7.5M | $17.7M | $32.9M | $30.2M | $22.4M | $10.7M | $12.4M | $16.9M |
| Operating income | — | — | — | — | — | -$30.2M | -$22.4M | -$10.7M | -$12.4M | — |
| Pre-tax income | -$10.3M | $7.5M | $6.9M | $17.9M | -$32.5M | -$28.8M | -$20.5M | -$9.8M | -$12.3M | -$16.8M |
| Income tax | $0 | — | — | — | — | $0 | $0 | $75.0K | $0 | $106.0K |
| Net income | -$10.3M | -$7.5M | -$6.9M | -$17.9M | -$32.5M | -$28.8M | -$20.5M | -$9.9M | -$12.3M | -$17.0M |
| EPS, basic | 2.39 | 8.08 | 30.00 | 127.80 | 19.80 | 1.35 | 0.97 | — | — | — |
| EPS, diluted | 2.39 | 8.08 | 30.00 | 127.80 | 19.80 | — | — | — | — | — |
| Shares, diluted (wtd. avg.) | 4.3M | 930,822 | 230,795 | 139,682 | 1.6M | 21.3M | 21.1M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.0M | $4.7M | $2.9M | $2.0M | $2.9M | $6.9M | $15.9M | $24.2M | $13.0M | $3.1M |
| Short-term investments | $7.0M | $7.2M | $7.5M | $11.8M | $31.9M | $40.1M | $27.9M | $6.1M | $0 | — |
| Receivables | — | $672.0K | $480.0K | $825.0K | $1.1M | $812.0K | $827.0K | $218.0K | $155.0K | $284.0K |
| Total current assets | $18.6M | $16.1M | $13.2M | $14.7M | $36.1M | $51.8M | $76.4M | $90.4M | $19.2M | $15.7M |
| Property, plant and equipment | — | — | $83.0K | $114.0K | $145.0K | $176.0K | $171.0K | $194.0K | $491.0K | $718.0K |
| Total assets | $18.6M | $18.5M | $16.6M | $16.6M | $36.6M | $52.4M | $77.1M | $90.6M | $19.6M | $16.4M |
| Accounts payable | $2.0M | $1.3M | $1.9M | $2.6M | $4.9M | $7.0M | — | — | — | $363.0K |
| Total current liabilities | $2.8M | $2.2M | $2.8M | $3.1M | $5.9M | $8.0M | $6.9M | $2.7M | $3.8M | $4.6M |
| Long-term debt | — | — | — | — | — | — | — | — | $0 | $796.0K |
| Retained earnings | -$210.8M | -$200.5M | -$193.0M | -$186.0M | -$168.2M | -$135.7M | -$106.9M | -$86.5M | -$76.6M | -$64.3M |
| Total equity | $15.8M | $16.3M | $13.9M | $13.4M | $30.5M | $44.2M | $69.9M | $87.9M | $15.8M | $11.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$6.3M | -$5.9M | -$6.1M | -$18.5M | -$32.9M | -$26.3M | -$14.9M | -$9.0M | -$12.1M | -$12.1M |
| Depreciation and amortisation | — | $80.0K | $30.0K | $60.0K | $42.0K | $39.0K | $35.0K | $387.0K | $239.0K | $169.0K |
| Stock-based compensation | $546.0K | $531.0K | $892.0K | $1.3M | $1.9M | $2.1M | $2.2M | $1.8M | $1.4M | $1.6M |
| Capital expenditure | — | — | — | $4.0K | $11.0K | $44.0K | $12.0K | $90.0K | $12.0K | $17.0K |
| Investing cash flow | -$3.4M | -$1.1M | $800.0K | $17.6M | $11.5M | $16.5M | $6.7M | -$60.0M | $6.4M | $6.3M |
| Financing cash flow | $9.0M | $8.8M | $6.2M | $70.0K | $17.4M | $768.0K | $143.0K | $80.2M | $15.5M | $4.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-014182.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- R&D
- Buybacks
- Receivables
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $14.3M | $9.7M | $8.3M | $18.2M | $26.1M | $27.2M | $13.0M | $3.6M | $3.0M | $4.9M |
| Buybacks | — | — | — | — | — | — | — | — | — | — |
| Receivables | $284.0K | $155.0K | $218.0K | $827.0K | $812.0K | $1.1M | $825.0K | $480.0K | $672.0K | — |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |